hepatic glucose production Inhibitors
1 drugsAbout hepatic glucose production
Hepatic glucose production is the process by which the liver generates glucose, crucial for maintaining energy balance. Dysregulation can lead to excessive glucose production, contributing to hyperglycemia and conditions like type 2 diabetes. Controlling hepatic glucose production is a key strategy in managing blood sugar levels.
Hepatic glucose production is a therapeutic target for metabolic disorders due to its role in blood sugar regulation. There is currently no genetic evidence available to support hepatic glucose production as a drug target.
XIGDUO XR (AstraZeneca) is the only FDA-approved drug that impacts hepatic glucose production, indicated for metabolic diseases. It is a small molecule approved in 2014, and no other drugs have been approved since.
Top hepatic glucose production Drugs
AstraZeneca is the only company with an approved drug targeting hepatic glucose production.
The market is not competitive, so new entrants may find opportunities for innovation.
hepatic glucose production Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets hepatic glucose production, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
hepatic glucose production Clinical Trials 422 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on hepatic glucose production. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 68 | 52 | 5 | 11 | 91% |
| Phase 2 | 96 | 45 | 12 | 39 | 79% |
| Phase 3 | 116 | 73 | 3 | 39 | 96% |
| Phase 4 | 142 | 90 | 13 | 38 | 87% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved hepatic glucose production drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting hepatic glucose production. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
hepatic glucose production Drug Approval Timeline (2014 - 2014)
The first and only drug, XIGDUO XR, was approved in 2014.
The approval timeline suggests a saturated market or challenges in developing new therapies for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 206 (27 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on hepatic glucose production. A trial counts if an approved drug acting on hepatic glucose production is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.